Incidence of venous thromboembolism in the setting of hematopoietic cell transplantation

V. J Daphne O'Hara, Trent Miller, Rakesh Mehta, Evonne Swartzendruber, Patrick J. Kiel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The underlying risk of venous thromboembolism (VTE) is unclear in patients undergoing hematopoietic cell transplantation (HCT). As such, these patients should still be considered at risk for development of VTE due to factors such as their underlying malignancy and the marked inflammatory state that develops from treatment. The purpose of this study was to characterize the incidence of VTE in patients undergoing HCT. Retrospective chart review of patients from the Indiana University Stem Cell Transplant Unit treated between January 1, 2008, and May 24, 2011. Patients were older than 18 years and had undergone HCT. The primary objective was to analyze the incidence of VTE in patients undergoing autologous HCT versus allogeneic HCT. Secondary objectives included documentation of VTE treatment strategies and time to occurrence of VTE. Of the 567 patients who underwent autologous HCT, 14 developed VTE (2.5%), whereas 5 of the 180 patients who underwent allogeneic HCT developed VTE (2.8%; P = 1.000). The median time to development of VTE from admission for HCT was 12 days in the autologous HCT arm versus 19 days in the allogeneic HCT arm (P = 0.610). The most commonly used VTE treatment strategy was enoxaparin (12 out of 19 VTEs). This study illustrates that VTE does occur rarely in patients who have undergone HCT. The optimal treatment regimen in this population requires further evaluation. Until a reliable protocol for treatment and evidence for risk factors are established, providers should be vigilant for occurrence of VTE in these patients.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalAmerican Journal of Therapeutics
Volume21
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Cell Transplantation
Venous Thromboembolism
Incidence
Arm
Enoxaparin
Therapeutics
Clinical Protocols
Documentation
Stem Cells

Keywords

  • anticoagulation
  • blood clot
  • hematopoietic cell transplantation
  • low molecular-weight heparin
  • stem cell transplantation
  • venous thromboembolism

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Incidence of venous thromboembolism in the setting of hematopoietic cell transplantation. / O'Hara, V. J Daphne; Miller, Trent; Mehta, Rakesh; Swartzendruber, Evonne; Kiel, Patrick J.

In: American Journal of Therapeutics, Vol. 21, No. 1, 01.2014, p. 15-19.

Research output: Contribution to journalArticle

O'Hara, V. J Daphne ; Miller, Trent ; Mehta, Rakesh ; Swartzendruber, Evonne ; Kiel, Patrick J. / Incidence of venous thromboembolism in the setting of hematopoietic cell transplantation. In: American Journal of Therapeutics. 2014 ; Vol. 21, No. 1. pp. 15-19.
@article{195fe08fda0f42309dcb6fb8f404280f,
title = "Incidence of venous thromboembolism in the setting of hematopoietic cell transplantation",
abstract = "The underlying risk of venous thromboembolism (VTE) is unclear in patients undergoing hematopoietic cell transplantation (HCT). As such, these patients should still be considered at risk for development of VTE due to factors such as their underlying malignancy and the marked inflammatory state that develops from treatment. The purpose of this study was to characterize the incidence of VTE in patients undergoing HCT. Retrospective chart review of patients from the Indiana University Stem Cell Transplant Unit treated between January 1, 2008, and May 24, 2011. Patients were older than 18 years and had undergone HCT. The primary objective was to analyze the incidence of VTE in patients undergoing autologous HCT versus allogeneic HCT. Secondary objectives included documentation of VTE treatment strategies and time to occurrence of VTE. Of the 567 patients who underwent autologous HCT, 14 developed VTE (2.5{\%}), whereas 5 of the 180 patients who underwent allogeneic HCT developed VTE (2.8{\%}; P = 1.000). The median time to development of VTE from admission for HCT was 12 days in the autologous HCT arm versus 19 days in the allogeneic HCT arm (P = 0.610). The most commonly used VTE treatment strategy was enoxaparin (12 out of 19 VTEs). This study illustrates that VTE does occur rarely in patients who have undergone HCT. The optimal treatment regimen in this population requires further evaluation. Until a reliable protocol for treatment and evidence for risk factors are established, providers should be vigilant for occurrence of VTE in these patients.",
keywords = "anticoagulation, blood clot, hematopoietic cell transplantation, low molecular-weight heparin, stem cell transplantation, venous thromboembolism",
author = "O'Hara, {V. J Daphne} and Trent Miller and Rakesh Mehta and Evonne Swartzendruber and Kiel, {Patrick J.}",
year = "2014",
month = "1",
doi = "10.1097/MJT.0b013e31829b59f5",
language = "English",
volume = "21",
pages = "15--19",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Incidence of venous thromboembolism in the setting of hematopoietic cell transplantation

AU - O'Hara, V. J Daphne

AU - Miller, Trent

AU - Mehta, Rakesh

AU - Swartzendruber, Evonne

AU - Kiel, Patrick J.

PY - 2014/1

Y1 - 2014/1

N2 - The underlying risk of venous thromboembolism (VTE) is unclear in patients undergoing hematopoietic cell transplantation (HCT). As such, these patients should still be considered at risk for development of VTE due to factors such as their underlying malignancy and the marked inflammatory state that develops from treatment. The purpose of this study was to characterize the incidence of VTE in patients undergoing HCT. Retrospective chart review of patients from the Indiana University Stem Cell Transplant Unit treated between January 1, 2008, and May 24, 2011. Patients were older than 18 years and had undergone HCT. The primary objective was to analyze the incidence of VTE in patients undergoing autologous HCT versus allogeneic HCT. Secondary objectives included documentation of VTE treatment strategies and time to occurrence of VTE. Of the 567 patients who underwent autologous HCT, 14 developed VTE (2.5%), whereas 5 of the 180 patients who underwent allogeneic HCT developed VTE (2.8%; P = 1.000). The median time to development of VTE from admission for HCT was 12 days in the autologous HCT arm versus 19 days in the allogeneic HCT arm (P = 0.610). The most commonly used VTE treatment strategy was enoxaparin (12 out of 19 VTEs). This study illustrates that VTE does occur rarely in patients who have undergone HCT. The optimal treatment regimen in this population requires further evaluation. Until a reliable protocol for treatment and evidence for risk factors are established, providers should be vigilant for occurrence of VTE in these patients.

AB - The underlying risk of venous thromboembolism (VTE) is unclear in patients undergoing hematopoietic cell transplantation (HCT). As such, these patients should still be considered at risk for development of VTE due to factors such as their underlying malignancy and the marked inflammatory state that develops from treatment. The purpose of this study was to characterize the incidence of VTE in patients undergoing HCT. Retrospective chart review of patients from the Indiana University Stem Cell Transplant Unit treated between January 1, 2008, and May 24, 2011. Patients were older than 18 years and had undergone HCT. The primary objective was to analyze the incidence of VTE in patients undergoing autologous HCT versus allogeneic HCT. Secondary objectives included documentation of VTE treatment strategies and time to occurrence of VTE. Of the 567 patients who underwent autologous HCT, 14 developed VTE (2.5%), whereas 5 of the 180 patients who underwent allogeneic HCT developed VTE (2.8%; P = 1.000). The median time to development of VTE from admission for HCT was 12 days in the autologous HCT arm versus 19 days in the allogeneic HCT arm (P = 0.610). The most commonly used VTE treatment strategy was enoxaparin (12 out of 19 VTEs). This study illustrates that VTE does occur rarely in patients who have undergone HCT. The optimal treatment regimen in this population requires further evaluation. Until a reliable protocol for treatment and evidence for risk factors are established, providers should be vigilant for occurrence of VTE in these patients.

KW - anticoagulation

KW - blood clot

KW - hematopoietic cell transplantation

KW - low molecular-weight heparin

KW - stem cell transplantation

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84894105608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894105608&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e31829b59f5

DO - 10.1097/MJT.0b013e31829b59f5

M3 - Article

VL - 21

SP - 15

EP - 19

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 1

ER -